| abstract |
Lycopene can be used in the primary prevention and incidence risk reduction of non-cancerous symptoms and/or pathologies (i.e., the prophylactic supplementation of the healthy subjects), in the treatment or the coadjuvant treatment of non-cancerous symptoms and/or pathologies (i.e. the supplementation as therapy or accompanying a running therapy) and in the secondary prevention of non-cancerous symptoms and/or pahtologies (i.e., the supplementation after a successful therapy for the prevention of the relapse), which are associated with, favored by or caused by androgen signalling or which are sensitive to a reduction of androgen signalling. |